Further, while previous reports have indicated that p53 activation may be involved in triggering ferroptosis in cancer cells (36), p53-null cancer cells undergo ferroptosis in response to eprenetapopt treatment, demonstrating that p53 reactivation is dispensable for ferroptosis induced by eprenetapopt. This evidence concerns the gene TP53 and cancer.